Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms

Simple item page
dc.contributor.authorRanson, Men_AU
dc.contributor.authorBerghofer, PJen_AU
dc.contributor.authorVine, KLen_AU
dc.contributor.authorGreguric, Ien_AU
dc.contributor.authorShepherd, Ren_AU
dc.contributor.authorKatsifis, Aen_AU
dc.date.accessioned2020-03-29T21:26:21Zen_AU
dc.date.available2020-03-29T21:26:21Zen_AU
dc.date.issued2012-08-01en_AU
dc.date.statistics2020-03-20en_AU
dc.description.abstractIntroduction Tumour-associated urokinase plasminogen activator (uPA) is a critical marker of invasion and metastasis, and it is recognised as having strong prognostic relevance as well as being a therapeutic target. The specific uPA inhibitor plasminogen activator inhibitor type-2 (PAI-2, SerpinB2) specifically targets cell bound uPA and is internalised. Furthermore, preclinical studies have established the “proof-of-principle” of uPA-targeting by PAI-2-cytotoxin conjugates in human carcinoma models. However, these studies also suggest that PAI-2 is rapidly cleared via the renal system with low total dose reaching the tumour. In this study, a comparative single photon emission computed tomography (SPECT) and biodistribution (BD) analysis of different forms of PAI-2 labelled with the radioisotopes iodine-123 (123I) and technetium-99m (99mTc) was undertaken. Methods The pharmacokinetic (PK) properties and BD of wild-type, ΔCD-loop and PEGylated ΔCD-loop PAI-2 labelled with the commonly used diagnostic SPECT radioisotopes 99mTc or 123I were compared in mouse models of human prostate carcinoma. Whole body SPECT imaging was also performed. Results Both wild-type and the shorter but active ΔCD-loop form of PAI-2 123I-labelled indirectly via conjugation to free amine groups (termed 123I-Bn-PAI-2) exhibited low tumour uptake, rapid excretion and similar PK profiles. Preliminary studies with a short branched-chain PEGylated 123I-Bn-PAI-2 ΔCD-loop indicated an increase in blood retention time and tumour uptake. All 123I-Bn-labelled radiotracers were largely excreted through the kidneys. By comparison, both wild-type 123I-PAI-2 (labelled directly via tyrosine residues) and 99mTc-PAI-2 displayed different PK/BD patterns compared to 123I-Bn-PAI-2, suggesting greater liver based catabolism and thus slower elimination. SPECT imaging mimicked the BD results of all radiotracers. © 2020 Elsevier B.V. Conclusion The different labelling methods gave distinct PAI-2 BD and tumour uptake profiles, with radioiodination resulting in the best non-tumour organ clearance profiles. Preliminary analyses with short branched-chain PEGylated 123I-Bn-PAI-2 ΔCD-loop suggest that further investigations with other PEGylation reagents are required to optimise this approach for tumour imaging. These findings impact on the use of PAI-2 for drug delivery and/or diagnostic development. © 2012 Published by Elsevier Inc.en_AU
dc.identifier.citationRanson, M., Berghofer, P., Vine, K. L., Greguric, I., Shepherd, R., & Katsifis, A. (2012). Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of plasminogen activator inhibitor Type 2 (PAI-2) forms. Nuclear Medicine and Biology, 39(6), 833-839. doi:10.1016/j.nucmedbio.2012.01.006en_AU
dc.identifier.govdoc8867en_AU
dc.identifier.issn0969-8051en_AU
dc.identifier.issue6en_AU
dc.identifier.journaltitleNuclear Medicine and Biologyen_AU
dc.identifier.pagination833-839en_AU
dc.identifier.urihttps://doi.org/10.1016/j.nucmedbio.2012.01.006en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/9288en_AU
dc.identifier.volume39en_AU
dc.language.isoenen_AU
dc.publisherElsevier B.V.en_AU
dc.subjectPlasminogenen_AU
dc.subjectEnzyme inhibitorsen_AU
dc.subjectLaboratory animalsen_AU
dc.subjectSingle photon emission computed tomographyen_AU
dc.subjectKineticsen_AU
dc.subjectPharmacologyen_AU
dc.subjectTechnetiumen_AU
dc.subjectNeoplasmsen_AU
dc.subjectTumor cellsen_AU
dc.titleDifferent radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) formsen_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles